6-{bis-[2-(4-benzyl-piperidin-1-yl)-2-oxo-ethyl]-amino}-hexanoic acid hydroxyamide | 853954-41-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 6-{bis-[2-(4-benzyl-piperidin-1-yl)-2-oxo-ethyl]-amino}-hexanoic acid hydroxyamide
• 英文别名: 6-[bis[2-(4-benzylpiperidin-1-yl)-2-oxoethyl]amino]-N-hydroxyhexanamide
• CAS: 853954-41-3
• 化学式: C₃₄H₄₈N₄O₄
• 分子量: 576.78
• InChiKey: KVEVQDHGVBMGLI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  42
• 可旋转键数：
  14
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  93.2
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• Diamine and Iminodiacetic Acid Hydroxamic Acid Derivatives
  申请人：Miller Thomas A.

  公开号：US20090023718A1

  公开（公告）日：2009-01-22

  The present invention relates to a novel class of hydroxamic acid derivatives having a diamine or iminodiacetic acid backbone. The hydroxamic acid compounds can be used to treat cancer. The hydroxamic acid compounds can also inhibit histone deacetylase and are suitable for use in selectively including terminal differentiation, arresting cell growth and/or apoptosis of neo-plastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compound of the invention are also useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases. The present invention further provides pharmaceutical compositions comprising the hydroxamic acid derivatives, and safe, dosing regimens of these pharmaceutical compositions, which are easy to follow, and which result in a therapeutically effective amount of the hydroxamic acid derivatives in vivo.

  本发明涉及一种新型的羟肟酸衍生物类，其具有二胺或亚胺二乙酸骨架。这些羟肟酸化合物可用于治疗癌症。这些羟肟酸化合物还可以抑制组蛋白去乙酰化酶，并适用于选择性地促进新生物细胞的终端分化，阻止细胞生长和/或细胞凋亡，从而抑制这些细胞的增殖。因此，本发明的化合物在治疗具有新生物细胞增殖特征的肿瘤患者中非常有用。该发明的化合物还可用于预防和治疗TRX介导的疾病，例如自身免疫、过敏和炎症性疾病，以及中枢神经系统（CNS）疾病的预防和/或治疗，例如神经退行性疾病。本发明还提供了包含羟肟酸衍生物的药物组合物，以及这些药物组合物的安全、剂量方案，易于遵循，并在体内产生治疗有效量的羟肟酸衍生物。
• DIAMINE AND IMINODIACETIC ACID HYDROXAMIC ACID DERIVATES
  申请人：Aton Pharma, Inc.

  公开号：EP1694329A2

  公开（公告）日：2006-08-30
• EP1694329A4
  申请人：——

  公开号：EP1694329A4

  公开（公告）日：2009-06-03
• [EN] DIAMINE AND IMINODIACETIC ACID HYDROXAMIC ACID DERIVATIVES<br/>[FR] DERIVES D'ACIDE HYDROXAMIQUE A BASE D'ACIDE DIAMINE ET IMINODIACETIQUE
  申请人：ATON PHARMA INC

  公开号：WO2005053610A2

  公开（公告）日：2005-06-16

  The present invention relates to a novel class of hydroxamic acid derivatives having a diamine or iminodiacetic acid backbone. The hydroxamic acid compounds can be used to treat cancer. The hydroxamic acid compounds can also inhibit histone deacetylase and are suitable for use in selectively including terminal differentiation, arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells, Thus, the compounds of the present are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compound of the invention are also useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases. The present invention further provides pharmaceutical compositions comprising the hydroxamic acid derivatives, and safe, dosing regimens of these pharmaceutical compositions, which are easy to follow, and which result in a therapeutically effective amount of the hydroxamic acid derivatives in vivo.